1-13 of 13
Keywords: Therapy
Close
Sort by
Journal Articles
Subject Area:
Oncology
Journal: Onkologie
Onkologie (2012) 35 (11): 690–693.
Published Online: 22 October 2012
... of a child who developed a CML as a second malignancy after DLBCL. Therapy-related CML and non-therapy-related secondary CML are discussed as potential explanations of this highly unusual clinical presentation. Conclusion: Hematological disorders such as CML may occur after lymphomas. With the increased use...
Journal Articles
Subject Area:
Oncology
Journal: Onkologie
Onkologie (2012) 35 (6): 350–356.
Published Online: 25 May 2012
... deletions were identified in 34% of patients whose cytogenetic status was analyzed. Symptomatic anemia was the major trigger for initiating therapy. 49% of patients received supportive care only, and 49% received active therapy (i.e., chemo-, immunomodulatory, or epigenetic therapy), including 5% who...
Journal Articles
Subject Area:
Oncology
Journal: Onkologie
Onkologie (2011) 34 (11): 634–637.
Published Online: 28 October 2011
... the first treatment option, and current data do not support adjuvant therapy. Systemic chemotherapy is mainly suggested for extensive disease while the long-term efficacy is unsatisfactory. The prognosis of IDCS seems to be associated with the initial stage of disease. 28 10 2011 © 2011 S...
Journal Articles
Subject Area:
Oncology
Journal: Onkologie
Onkologie (2011) 34 (4): 184–188.
Published Online: 18 March 2011
... Keywords Doxorubicin · Non-Hodgkin s lymphoma · Age · Therapy Schlüsselwörter Doxorubicin · Non-Hodgkin-Lymphom · Alter · Therapie Summary Background: We retrospectively evaluated the efficacy and safety of individualized liposomal doxorubicin-based treatment in elderly patients with non-Hodgkin s lymphoma...
Journal Articles
Subject Area:
Oncology
Journal: Onkologie
Onkologie (2011) 34 (3): 117–120.
Published Online: 18 February 2011
... to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer...
Journal Articles
Subject Area:
Oncology
Journal: Onkologie
Onkologie (2010) 33 (11): 604–610.
Published Online: 15 October 2010
... was determined in more than 2/3 of patients. Overall, 35% of patients were considered for high-dose chemotherapy. As a consequence of the development of innovative substances, there are remarkable shifts in first line, second line, and third line therapy with an increase in the use of bortezomib at all levels...
Journal Articles
Subject Area:
Oncology
Journal: Onkologie
Onkologie (2009) 32 (10): 591–594.
Published Online: 14 September 2009
... with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes...
Journal Articles
Subject Area:
Oncology
Journal: Onkologie
Onkologie (1994) 17 (4): 384–389.
Published Online: 11 May 2009
... curative results. While adjuvant therapy is not necessarily required in stage-IEl tumors, postoperative chemotherapy or radiation are mandatory in the other stages or in residual disease. Multimodal therapy in stages IE and HE results in favorable prognosis as indicated by a 5-year survival rate of 75-90...
Journal Articles
Subject Area:
Oncology
Journal: Onkologie
Onkologie (1994) 17 (4): 358–366.
Published Online: 11 May 2009
... recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications...
Journal Articles
Subject Area:
Oncology
Journal: Onkologie
Onkologie (1995) 18 (2): 110–121.
Published Online: 11 May 2009
...P. Wust; B. Rau; M. Gremmler; P. Schlag; A. Jordan; J. Löffel; H. Riess; R. Felix Hyperthermia can play a role in curative multimodal therapies of locally advanced malignancies. Firstly, the downstaging rate can be increased in pre-operative therapies (resectability, organ preservation...
Journal Articles
Subject Area:
Oncology
Journal: Onkologie
Onkologie (1992) 15 (3): 209–220.
Published Online: 29 April 2009
... depends primarily on patho-histological parameters of the primary, as well as on therapeutic modalities and quality, too. For this reason, the arguments for routine neo- or adjuvant radio-(chemo-)therapy, increasingly arising during the last two years, is debatable. Global recommendations do not realize...
Journal Articles
Subject Area:
Oncology
Journal: Onkologie
Onkologie (1984) 7 (1): 27–31.
Published Online: 21 April 2009
... are changing. In these cases the DNA photometry may support the histologic diagnosis of invasive growth and facilitate the choice of therapy. Minimal invasive endometrial cancer DNA Diagnosis Therapy Onkologie 7:27-31 (1/1984) Histographic DNA Pattern as an Aid for Diagnosis and Therapy of Minimal...
Journal Articles
Subject Area:
Oncology
Journal: Onkologie
Onkologie (2009) 32 (5): 277–279.
Published Online: 20 April 2009
..., as should rare triggering conditions like amegakaryocytic TP when evaluating therapeutic opportunities in thrombocytopenic patients. Thrombocytopenia, amegakaryocytic Small-cell lung cancer Diagnosis Therapy Clinical Case · Kasuistik Onkologie 2009;32:277 279 DOI: 10.1159/000209318 Published...